Navigation Links
CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings

on is a biopharmaceutical company developing diverse approaches, including novel protein, antibody, antibody- drug conjugate and small molecule therapeutics. By leveraging the drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of patients with cancer and inflammatory diseases. CuraGen is focused on bringing velafermin, belinostat and CR011-vcMMAE through clinical development, and maintains a portfolio of earlier-stage compounds that have the potential to treat cancer and inflammatory diseases. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit http://www.curagen.com.

About TopoTarget

TopoTarget (CSE: TOPO) is a biopharmaceutical company, headquartered in Denmark and with subsidiaries in the UK and Germany, dedicated to finding "Answers for Cancer" and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer enzyme regulators (mainly HDAC, mTOR, and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule preclinical drug candidates and seven drugs are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene(TM) is TopoTarget's first product on the market. In addition to organic growth, TopoTarget consistently looks for opportunities to strengthen and expand its activities through acquisitions and in-licensing. For more information, please refer to http://www.topotarget.com.

Safe Harbor

Statements in this pr
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for Belinostat
2. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:5/15/2008)...search reflects depth and breadth of, collaborati...atments for diverse forms o...f Zometa(R), the leading IV, bisphosphonate, on re...cer, - Four oral sessions to feature RAD001, firs...ncluding first results of RECORD-1 study in renal ...
(Date:5/15/2008)... France, May 15 /- Cerenis,Therapeuti...ompany,developing HDL-related compounds for the tr...today announced that it has completed a Phase I,cl...d product candidates.,CER-002 is a peroxisome prol...agonist in development for the treatment of cardio...
(Date:5/15/2008)...or an Antiplatelet Therapy that, Combined, with As...f Plavix/Iscover and Aspirin, According to a N..., May 15 /- Decision Resources, one o...for pharmaceutical and,healthcare issues, finds th...vement in patient compared to Sanofi-Aventis/Brist...
(Date:5/15/2008)...swire/ -- Omega 3 fatty acids bound to,phospholipi... natural,alternative and may have beneficial effec...French study reveals. While several studies have r...vity, French researchers have,hypothesized that Ve...,impulse control., These research findings have l...
Breaking Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3A step toward tissue engineered heart structures for children 355 1A step toward tissue engineered heart structures for children 355 2Microbiotic technology developed for microinjection of zebrafish embryos 1069 1Mathematics might save you a trip to the ER 1066 1Mathematics might save you a trip to the ER 1066 2Thousands of starving children could be restored to health with peanut butter program 353 1Thousands of starving children could be restored to health with peanut butter program 353 2Thousands of starving children could be restored to health with peanut butter program 353 3
...tients Achieved at Least 75 Percent Improvement in...of Five Dosing Groups, More,Than Half Achieved 90 ...07 /PRNewswire-FirstCall/ -- New,Phase II study re...-874, reduced psoriasis symptoms significantly in ...e out of 10 patients with,moderate to severe psori...
...-(BUSINESS WIRE)--May 3, 2007 - New data show the,...ction of chorea,associated with Huntington,s disea...ssfully completed treatment in a 13-week trial.,Th...ccessfully to,sustain reduced chorea burden in lon...tial benefit of,tetrabenazine as maintenance thera...
Other Medicine Technology:Abbott's Investigational Treatment ABT-874 Shows Positive Results,in Phase II Psoriasis Study 2Abbott's Investigational Treatment ABT-874 Shows Positive Results,in Phase II Psoriasis Study 3Abbott's Investigational Treatment ABT-874 Shows Positive Results,in Phase II Psoriasis Study 4Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 2Clinical Trial Results Suggest Long-Term Treatment Benefit of,Tetrabenazine for Chorea Associated with Huntington's Disease 3
(Date:5/16/2008)...EWPORT BEACH, Calif., May 16 /PRNewswire-FirstCall...P ) announced today the promotion of David,M. Boit... Officer. "Dave,has made a tremendous contribution...y our strong investment growth and diversification... over $1 billion in accretive,investments for NHP,...
(Date:5/16/2008)...AN DIEGO, May 16 /PRNewswire-FirstCall/ -- CryoCor...cused on the treatment of cardiac,arrhythmias, ann...ers of,CryoCor common stock filed a complaint in t...ty of San Diego, naming as defendants each member ...Boston Scientific Corporation.,The complaint is st...
(Date:5/16/2008)...ment guidelines quickly disseminated to community ...16 (HealthDay News) -- Partnerships between major ...e a quick and effective way to spread cancer treat... Center in Philadelphia. , Most new cancer trea...ost cancer care is provided at community hospitals...
(Date:5/16/2008)...ismatch in some early stage cases makes therapy of...RIDAY, May 16 (HealthDay News) -- Colon cancer pat...need to receive chemotherapy. In fact, not only do..., it may actually harm them, a new study found. ,...ncer], then you should not be treated with chemoth...
Breaking Medicine News(10 mins):Health News:David M. Boitano Promoted to Senior Vice President 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 3Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 4Health News:Partnerships Effective Communicators of Cancer Advances 2Health News:Not All Colon Cancer Patients Need Chemotherapy: Study 2
...eening system combining digital photography with I...method to screen for a common childhood oral disea...ty toddlers. Early childhood dental caries (ECC... tooth decay, results from prolonged exposure to s...
...study published in the journal, Cell Metabolism, r...ion in the zebrafish that are remarkably similar t...es disease that could aid in finding new therapies...ead to the aquarium fish becoming an important ani...
... mothers may someday get a personalized menu of fo...netic makeup as a result of new research at Washin... Researchers used transparent fish embryos to dev...genes and diet interact to cause birth defects. "...
...can children with asthma make more clinic visits t... severity.// Asthma has been on the rise for the ... especially high prevalence. A study in the August...hat Puerto Rican children with asthma make more cl...
Other Medicine News:Health News:New Screening System For Early Detection Of Dental Caries in Toddlers 2Health News:New Screening System For Early Detection Of Dental Caries in Toddlers 3Health News:New Studies On Zebrafish Could Aid in Treating Birth Defects 2Health News:New Studies On Zebrafish Could Aid in Treating Birth Defects 3Health News:New Studies On Zebrafish Could Aid in Treating Birth Defects 4Health News:Unmasking Nutrition's Role in Genes and Birth Defects 2Health News:Unmasking Nutrition's Role in Genes and Birth Defects 3Health News:Children of Different Race Show Different Patterns of Asthma Care 2
Self retaining brain retractor.
The Budde Halo brain retractor is designed for use in all intercranial procedures where retraction of delicate brain tissue is required.
Langenbeck periosteal elevators, wide, blade width 11/16" (17 mm), length 7 1/2" (191 mm).
Cushing periosteal elevators, Gutsch handle, sharp, narrow, blade width 3/16" (5 mm), length 7 5/8" (194 mm).
Medicine Products: